...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Bradykinin in ischemic conditioning-induced tissue protection: Evidences and possible mechanisms
【24h】

Bradykinin in ischemic conditioning-induced tissue protection: Evidences and possible mechanisms

机译:缓激肽在缺血性调节诱导的组织保护中的证据和可能的机制

获取原文
获取原文并翻译 | 示例
           

摘要

Ischemic conditioning is an intrinsic protective mechanism in which repeated short episodes of reversible ischemia protects the tissue and increases its tolerance against a subsequent longer period of ischemia (index ischemia). Bradykinin is a physiologically and pharmacologically active peptide of the kallikrein-kinin system. Besides the involvement of bradykinin in a variety of physiological and pathological responses such as pain, inflammation and in cardiovascular system as a potent vasodilator, it also acts as an endogenous cytoprotective mediator in the ischemic tissue. Pretreatment with various pharmacological modulators of bradykinin has confirmed the involvement of bradykinin in ischemic conditioning-induced protection. The protective actions of bradykinin in three major paradigms of ischemic conditioning i.e. ischemic preconditioning, ischemic postconditioning and remote ischemic preconditioning involves activation and regulation of various endogenous signaling cascades to render the heart resistant to infarction. In ischemic preconditioning, bradykinin exerts cardioprotective effect via activation of PI3K/Akt/eNOS signaling pathway and regulation of redox state via NO release. The role of bradykinin and its B-2 receptors in ischemic-postconditioning induced neuroprotection has been described mainly due to its increased redox signaling cascade and activation of mitochondrial anti-apoptotic pathway. Furthermore, its cardioprotective role during remote ischemic preconditioning has been associated with activation of B2 receptors mediated neurogenic pathway and internalization of B2 receptors along with the formation of signalosomes that activates intracellular cytoprotective transduction pathways. The present review focuses on the potential role of bradykinin in mediating different forms of ischemic conditioning (pre/post/remote)-induced cardioprotection and neuroprotection along with the possible mechanisms. (C) 2015 Elsevier B.V. All rights reserved.
机译:缺血性调节是一种内在的保护机制,其中反复出现的短时间的可逆性缺血可保护组织并提高其对随后较长时间的缺血(指数缺血)的耐受性。缓激肽是激肽释放酶激肽系统的生理和药理活性肽。除了缓激肽作为有效的血管扩张剂参与各种生理和病理反应(例如疼痛,炎症和心血管系统)外,它还充当缺血组织的内源性细胞保护介质。用缓激肽的各种药理调节剂进行的预处理已证实,缓激肽参与了缺血性调理诱导的保护作用。缓激肽在缺血性调节的三个主要范例中的保护作用,即缺血性预处理,缺血性后处理和远程缺血性预处理涉及激活和调节各种内源性信号传导级联,从而使心脏对梗塞具有抵抗力。在缺血预处理中,缓激肽通过激活PI3K / Akt / eNOS信号通路和通过释放NO调节氧化还原状态来发挥心脏保护作用。缓激肽及其B-2受体在缺血后处理诱导的神经保护中的作用已被描述,主要是由于其增加的氧化还原信号级联和线粒体抗凋亡途径的激活。此外,其在远程缺血预处理中的心脏保护作用与B2受体介导的神经源性途径的激活和B2受体的内在化以及激活细胞内细胞保护性转导途径的信号小体的形成有关。本文综述了缓激肽在介导不同形式的缺血性调节(预处理/后/远程)诱导的心脏保护和神经保护以及潜在机制中的潜在作用。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号